The efficacy of Austedo in the treatment of tardive dyskinesia was established in two Phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel group studies (AIM-TD and ARM-TD). The trials included 335 adult ambulatory patients with tardive duskinesia caused by use of dopamine receptor antagonists (ie, antipsychotics, metoclopramide). Compared to placebo, patients taking Austedo had a statistically significant improvement in Abnormal Involuntary Movement Scale (AIMS), the primary efficacy measure.
Austedo, a vesicular monoamine transporter 2 (VMAT2) inhibitor, was initially approved to treat Huntington’s chorea in April 2017. The product is available as 6mg, 9mg, and 12mg strength tablets in 60-count bottles.
For more information call (888) 483-8279 or visit Austedo.com.